Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Genomics Company Human Longevity Names New CEO

XTALKS VITALS NEWS

Craig Venter

Just one month ago, Venter revealed that genomic tests conducted at his health clinic, Health Nucleus, identified the presence of prostate cancer.

Share this!

January 6, 2017 | by Sarah Hand, M.Sc.

Co-founder and CEO of Human Longevity Inc. (HLI), J. Craig Venter, made a surprise announcement on Wednesday that he would be stepping down as head of the genomics company. Venter’s replacement – Cynthia Collins – is set to take his place as of January 9, 2017.

Collins has extensive experience in the life science sector, with her most recent role being CEO/ General Manager for the Cell Therapy and Purification and Analysis Businesses for GE Healthcare. She will also join the HLI Board of Directors, which will continue to be led by Venter in his role as Executive Chairman.

“We are extremely pleased to have Cindy join HLI as our new CEO. Her wide-ranging experience in leading and growing commercial operations for privately-held and publicly-traded life science businesses, will be invaluable to HLI,” said Venter in a press release about the change in leadership. “2017 will be a key year for HLI with the launch and expansion of many of our products including oncology, whole genome, HLI Knowledgebase™, HLI Search™, and the HLI Health Nucleus™. Cindy’s combination of innovative business leadership, coupled with commercialization and operations acumen in a variety of life science arenas, is the perfect skill set to bring our vision of high quality, genomic-powered products to the global marketplace.”



Just one month ago, Venter revealed that genomic tests conducted at his health clinic, Health Nucleus, identified the presence of prostate cancer. Due to the predicted aggressiveness of the disease, Venter underwent prostate surgery.

According to Venter, his levels of prostate-specific antigen (PSA) protein were not elevated, and there were no other indications that he might have prostate cancer. A spokesperson for the company said Venter’s health was not a factor in the decision.

“HLI represents a tremendous opportunity to change healthcare and improve patient outcomes,” said Collins. “I cannot imagine a more perfect union of my combined experience in diagnostics, therapeutics, and life sciences and in leading organizations through multiple phases of their life cycles to create value. I believe my capabilities and experience, combined with Dr. Venter’s scientific success and vision, are highly complementary and will create a solid foundation for HLI’s future.”

Venter’s genome was the first human genome to be published in its entirety in 2007. HLI aims to use its comprehensive database of genomic, phenotypic and clinical data to make novel discoveries in medicine.


Keywords: Genomics, Human Genome, Life Science


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.